On March 31, 2026, AIB purchased from the Issuer (i) 3,998,332 shares of the Issuer's Class A Common Stock at a purchase price of $4.15 per share and (ii) 5,640,222 pre-funded warrants to purchase shares of Class A Common Stock, each whole pre-funded warrant entitling AIB to purchase one share of Class A Common Stock at an exercise price of $0.0001 per share (the "Pre-Funded Warrants"), at a purchase price of $4.1499 per pre-funded warrant, pursuant to a Securities Purchase Agreement by and among the Issuer and the investors party thereto dated as of March 27, 2026 (the "Securities Purchase Agreement"). AIB funded this purchase using capital contributed from affiliated entities, which funded that capital using cash on hand. Pursuant to the Securities Purchase Agreement, AIB was granted a board designation right, and Dr. Liam Ratcliffe was appointed to the Issuer's board of directors in connection therewith, subject to AIB continuing to own at least 50% of the Securities purchased by AIB at the closing of the private placement. In connection with the purchase and sale of shares of Class A Common Stock and Pre-Funded Warrants, the Issuer and the parties to the Securities Purchase Agreement entered into a registration rights agreement, dated as of March 27, 2026 (the "Registration Rights Agreement"), providing for the registration for resale of the shares of Class A Common Stock and the shares of Class A Common Stock issuable upon exercise of the Pre-Funded Warrants, pursuant to a registration statement to be filed with the SEC within 30 days after the closing. The Issuer agreed to use reasonable best efforts to have such registration statement declared effective at the earliest possible date but no later than the earlier of (i) the 90th calendar day after the date of the Registration Rights Agreement, (ii) the 120th calendar day following the initial filing date of such registration statement if the SEC notifies the Issuer that it will "review" such registration statement and (iii) the 5th business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that such registration statement will not be "reviewed" or will not be subject to further review. The Issuer also agreed to keep such registration statement continuously effective until the earlier of (i) the date that all shares covered by such registration statement have been sold or (ii) the date on which such shares may be resold without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Issuer to be in compliance with the current public information requirement under Rule 144 under the Securities Act of 1933, as amended, or any other rule of similar effect. Each Pre-Funded Warrant is exercisable immediately at an exercise price of $0.0001 per share of Class A Common Stock and will not expire until exercised in full. AIB may not exercise a Pre-Funded Warrant if AIB, together with its attribution parties, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended. AIB may increase or decrease such percentage, not in excess of 19.99%, by providing at least 61 days' prior notice to the Issuer. The Pre-Funded Warrants are subject to the Beneficial Ownership Blocker described in Item 5 herein. The foregoing descriptions of the Securities Purchase Agreement, the Registration Rights Agreement and the Pre-Funded Warrants do not purport to be complete and are qualified in their entirety by reference to the Securities Purchase Agreement, the Registration Rights Agreement and the form of Pre-Funded Warrant, each of which is incorporated herein by reference to the Current Report on Form 8-K filed by the Issuer with the SEC on March 30, 2026 and identified as Exhibits 99.1, 99.2 and 99.3 hereto.

The information set forth in Item 3 hereof is incorporated herein by reference. A Joint Filing Agreement, dated as of April 7, 2026, by and among the Reporting Persons has been executed by the Reporting Persons, a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

99.1 Form of Securities Purchase Agreement, dated as of March 27, 2026, by and among OnKure Therapeutics, Inc. and the other parties signatories thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on March 30, 2026). 99.2 Form of Registration Rights Agreement, dated as of March 27, 2026, by and among OnKure Therapeutics, Inc. and the other parties signatories thereto (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Issuer with the SEC on March 30, 2026). 99.3 Form of Pre-Funded Warrant, by and between OnKure Therapeutics, Inc. and AI Biotechnology LLC (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on March 30, 2026). 99.4 Joint Filing Agreement, dated as of April 7, 2026. 99.5 Limited Power of Attorney, dated as of April 7, 2026.